Proposed Medicare Local Coverage Determination published by Palmetto GBA’s MolDX Program triggers comment period in advance of public meeting The clinical guideline first reiterates the ACG’s ...
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned ...
Management reiterated confidence that the next step is the publication of a draft local coverage determination (LCD) for EsoGuard, following the CAC meeting. Aklog stated, "we are very confident that ...
First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida "This expansion into mobile testing is ...
BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry “We believe EsoGuard, the first and only commercially available diagnostic ...
NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary ...
Lucid Diagnostics' (NASDAQ:LUCD) EsoGuard test could get Medicare coverage soon, according to recent commentary from BTIG analysts. Analysts at BTIG said that during a day of investor meetings with ...
According to Needham, Lucid Diagnostics Inc. (NASDAQ:LUCD) is likely to receive approval for EsoGuard testing-related Medicare reimbursement, which would boost testing volumes. The Lucid Diagnostics ...
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results